What to expect in 2024: important health economics and outcomes research (HEOR) trends
J Med Econ. 2024 Jan-Dec;27(1):69-76. doi: 10.1080/13696998.2023.2291604. Epub 2023 Dec 20.NO ABSTRACTPMID:38122829 | DOI:10.1080/13696998.2023.2291604 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 20, 2023 Category: Health Management Authors: Ivo Abraham Mickael Hiligsmann Kenneth K C Lee Leslie Citrome Giorgio L Colombo Mike Gregg Source Type: research
Cost-effectiveness of intravenous resuscitation fluids in sepsis patients: A patient-level data analysis in Jordan
Conclusion: IV Albumin use in sepsis patients might not be cost-effective from the healthcare perspective of Jordan. This has important implications for policymakers to readdress Albumin prescribing practice in sepsis patients.PMID:38105744 | DOI:10.1080/13696998.2023.2296196 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 18, 2023 Category: Health Management Authors: Shoroq M Altawalbeh Eman M Almestarihi Rawand A Khasawneh Suleiman M Momany Khawla AbuHammour Mohammad S Shawaqfeh Ivo Abraham Source Type: research
Clinical and economic impact of ventricular assist device infections: a real-world claims analysis
CONCLUSIONS: VAD infections were associated with higher mortality, more healthcare utilization, and higher total cost. Strategies to minimize VAD-specific infections could lead to improved clinical and economic outcomes.PMID:38084737 | DOI:10.1080/13696998.2023.2292912 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 12, 2023 Category: Health Management Authors: Anton Y Peleg Erika D Feller Marcus M üller Sebastian Schulte-Eistrup David McGiffin Daniel Zimpfer Reece Holbrook Jamie Margetta Swathi Seshadri Nahush A Mokadam Source Type: research
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
CONCLUSIONS: This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.PMID:38085684 | DOI:10.1080/13696998.2023.2293379 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 12, 2023 Category: Health Management Authors: T Spelman W L Herring C Acosta R Hyde V G Jokubaitis E Pucci A Lugaresi G Laureys E K Havrdova D Horakova G Izquierdo S Eichau S Ozakbas R Alroughani T Kalincik P Duquette M Girard T Petersen F Patti T Csepany F Granella F Grand'Maison D Ferraro R Karabud Source Type: research
Clinical and economic impact of Ventricular Assist Device infections: a real-world claims analysis
CONCLUSIONS: VAD infections were associated with higher mortality, more healthcare utilization, and higher total cost. Strategies to minimize VAD-specific infections could lead to improved clinical and economic outcomes.PMID:38084737 | DOI:10.1080/13696998.2023.2292912 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 12, 2023 Category: Health Management Authors: Anton Y Peleg Erika D Feller Marcus M üller Sebastian Schulte-Eistrup David McGiffin Daniel Zimpfer Reece Holbrook Jamie Margetta Swathi Seshadri Nahush A Mokadam Source Type: research
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
CONCLUSIONS: This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.PMID:38085684 | DOI:10.1080/13696998.2023.2293379 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 12, 2023 Category: Health Management Authors: T Spelman W L Herring C Acosta R Hyde V G Jokubaitis E Pucci A Lugaresi G Laureys E K Havrdova D Horakova G Izquierdo S Eichau S Ozakbas R Alroughani T Kalincik P Duquette M Girard T Petersen F Patti T Csepany F Granella F Grand'Maison D Ferraro R Karabud Source Type: research
Clinical and economic impact of Ventricular Assist Device infections: a real-world claims analysis
CONCLUSIONS: VAD infections were associated with higher mortality, more healthcare utilization, and higher total cost. Strategies to minimize VAD-specific infections could lead to improved clinical and economic outcomes.PMID:38084737 | DOI:10.1080/13696998.2023.2292912 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 12, 2023 Category: Health Management Authors: Anton Y Peleg Erika D Feller Marcus M üller Sebastian Schulte-Eistrup David McGiffin Daniel Zimpfer Reece Holbrook Jamie Margetta Swathi Seshadri Nahush A Mokadam Source Type: research
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
CONCLUSIONS: This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.PMID:38085684 | DOI:10.1080/13696998.2023.2293379 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 12, 2023 Category: Health Management Authors: T Spelman W L Herring C Acosta R Hyde V G Jokubaitis E Pucci A Lugaresi G Laureys E K Havrdova D Horakova G Izquierdo S Eichau S Ozakbas R Alroughani T Kalincik P Duquette M Girard T Petersen F Patti T Csepany F Granella F Grand'Maison D Ferraro R Karabud Source Type: research
Clinical and economic impact of Ventricular Assist Device infections: a real-world claims analysis
CONCLUSIONS: VAD infections were associated with higher mortality, more healthcare utilization, and higher total cost. Strategies to minimize VAD-specific infections could lead to improved clinical and economic outcomes.PMID:38084737 | DOI:10.1080/13696998.2023.2292912 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 12, 2023 Category: Health Management Authors: Anton Y Peleg Erika D Feller Marcus M üller Sebastian Schulte-Eistrup David McGiffin Daniel Zimpfer Reece Holbrook Jamie Margetta Swathi Seshadri Nahush A Mokadam Source Type: research
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
CONCLUSIONS: This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.PMID:38085684 | DOI:10.1080/13696998.2023.2293379 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 12, 2023 Category: Health Management Authors: T Spelman W L Herring C Acosta R Hyde V G Jokubaitis E Pucci A Lugaresi G Laureys E K Havrdova D Horakova G Izquierdo S Eichau S Ozakbas R Alroughani T Kalincik P Duquette M Girard T Petersen F Patti T Csepany F Granella F Grand'Maison D Ferraro R Karabud Source Type: research
Clinical and economic impact of Ventricular Assist Device infections: a real-world claims analysis
CONCLUSIONS: VAD infections were associated with higher mortality, more healthcare utilization, and higher total cost. Strategies to minimize VAD-specific infections could lead to improved clinical and economic outcomes.PMID:38084737 | DOI:10.1080/13696998.2023.2292912 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 12, 2023 Category: Health Management Authors: Anton Y Peleg Erika D Feller Marcus M üller Sebastian Schulte-Eistrup David McGiffin Daniel Zimpfer Reece Holbrook Jamie Margetta Swathi Seshadri Nahush A Mokadam Source Type: research
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
CONCLUSIONS: This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.PMID:38085684 | DOI:10.1080/13696998.2023.2293379 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 12, 2023 Category: Health Management Authors: T Spelman W L Herring C Acosta R Hyde V G Jokubaitis E Pucci A Lugaresi G Laureys E K Havrdova D Horakova G Izquierdo S Eichau S Ozakbas R Alroughani T Kalincik P Duquette M Girard T Petersen F Patti T Csepany F Granella F Grand'Maison D Ferraro R Karabud Source Type: research
A real-world assessment of healthcare costs associated with agitation in Alzheimer's dementia
CONCLUSIONS: Among patients with AD, agitation was associated with shorter time to death/institutionalization and increased comorbidities, medication use, and healthcare costs, highlighting the additional clinical and economic burden that agitation poses to patients and the healthcare system.PMID:38073468 | DOI:10.1080/13696998.2023.2291966 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 11, 2023 Category: Health Management Authors: George Grossberg Annette Urganus Jeff Schein Rebecca Bungay Martin Cloutier Marjolaine Gauthier-Loiselle Deborah Chan Annie Guerin Jyoti Aggarwal Source Type: research
